We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Unlocking Q1 Potential of Quest Diagnostics (DGX): Exploring Wall Street Estimates for Key Metrics
Read MoreHide Full Article
In its upcoming report, Quest Diagnostics (DGX - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $1.86 per share, reflecting a decline of 8.8% compared to the same period last year. Revenues are forecasted to be $2.29 billion, representing a year-over-year decrease of 1.7%.
The consensus EPS estimate for the quarter has undergone an upward revision of 0.1% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
Given this perspective, it's time to examine the average forecasts of specific Quest Diagnostics metrics that are routinely monitored and predicted by Wall Street analysts.
The consensus estimate for 'Net revenues- Diagnostic Information Services revenues' stands at $2.22 billion. The estimate indicates a year-over-year change of -1.9%.
Analysts predict that the 'Net revenues- All other operating segments' will reach $72.14 million. The estimate suggests a change of +0.2% year over year.
The consensus among analysts is that 'Net revenues- Base business revenues' will reach $2.29 billion. The estimate indicates a year-over-year change of +3.3%.
The combined assessment of analysts suggests that 'Net revenues- COVID-19 testing revenues' will likely reach $9.61 million. The estimate indicates a year-over-year change of -91.9%.
Shares of Quest Diagnostics have experienced a change of -0.7% in the past month compared to the -4% move of the Zacks S&P 500 composite. With a Zacks Rank #4 (Sell), DGX is expected to underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Unlocking Q1 Potential of Quest Diagnostics (DGX): Exploring Wall Street Estimates for Key Metrics
In its upcoming report, Quest Diagnostics (DGX - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $1.86 per share, reflecting a decline of 8.8% compared to the same period last year. Revenues are forecasted to be $2.29 billion, representing a year-over-year decrease of 1.7%.
The consensus EPS estimate for the quarter has undergone an upward revision of 0.1% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
Given this perspective, it's time to examine the average forecasts of specific Quest Diagnostics metrics that are routinely monitored and predicted by Wall Street analysts.
The consensus estimate for 'Net revenues- Diagnostic Information Services revenues' stands at $2.22 billion. The estimate indicates a year-over-year change of -1.9%.
Analysts predict that the 'Net revenues- All other operating segments' will reach $72.14 million. The estimate suggests a change of +0.2% year over year.
The consensus among analysts is that 'Net revenues- Base business revenues' will reach $2.29 billion. The estimate indicates a year-over-year change of +3.3%.
The combined assessment of analysts suggests that 'Net revenues- COVID-19 testing revenues' will likely reach $9.61 million. The estimate indicates a year-over-year change of -91.9%.
View all Key Company Metrics for Quest Diagnostics here>>>
Shares of Quest Diagnostics have experienced a change of -0.7% in the past month compared to the -4% move of the Zacks S&P 500 composite. With a Zacks Rank #4 (Sell), DGX is expected to underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>